2023 World Conference on Lung Cancer (Posters)-EP08.02. Evaluation of Treatment Strategies for Patients with Stage IIIA Non-Small Cell Lung Cancer in the Immunotherapy Era

EP08.02. Evaluation of Treatment Strategies for Patients with Stage IIIA Non-Small Cell Lung Cancer in the Immunotherapy Era - PDF(Slides)

Back to course

Pdf Summary

This document presents a study evaluating the treatment strategies for patients with stage IIIA non-small cell lung cancer (NSCLC). The study aims to compare the survival outcomes between surgery with neoadjuvant or adjuvant chemotherapy (SC) and chemoradiotherapy with consolidation immunotherapy (CRI) in this patient population.<br /><br />The study found that overall survival (OS) and progression-free survival (PFS) were consistently higher for patients treated with SC compared to CRI. The median OS and PFS were approximately 1 year longer for patients treated with SC. <br /><br />The study also examined the treatment patterns for stage IIIA NSCLC since 2017. It showed that the probability of treatment with surgery plus chemotherapy varied widely among different oncology practices. This suggests an opportunity to improve survival and PFS among potentially resectable patients who are currently only offered chemoradiotherapy with or without consolidation immunotherapy.<br /><br />The distribution of treatment modalities by practice organization showed that a significant proportion of patients received chemoradiotherapy with or without consolidation immunotherapy, while a smaller percentage underwent surgery alone or systemic therapy or radiation alone.<br /><br />The study highlights the need for clear and objective guidance in determining the resectability of stage IIIA NSCLC, as the determination of resectability was found to be subjective and inconsistent. This guidance could help improve patient care, especially for those who are not considered traditional surgical candidates.<br /><br />In conclusion, the study suggests that surgery with neoadjuvant or adjuvant chemotherapy may provide better survival outcomes for patients with stage IIIA NSCLC compared to chemoradiotherapy with consolidation immunotherapy. However, further research and clear guidelines are needed to optimize the treatment approach for this patient population.

Asset Subtitle

Amy Alabaster

Meta Tag

Speaker Amy Alabaster

Topic Local-Regional NSCLC: Multimodality Therapy

Keywords

stage IIIA non-small cell lung cancer

treatment strategies

surgery with neoadjuvant chemotherapy

surgery with adjuvant chemotherapy

chemoradiotherapy with consolidation immunotherapy

overall survival

progression-free survival

treatment patterns

resectability of NSCLC

patient care